 Non-small cell lung cancer, NSCLC, is driven by epidermal growth factor receptor, EGFR, mutations. EGFR tyrosine kinase inhibitors have been effectively used for clinical treatment, but patients eventually develop drug resistance. Resistance to EGFR-TK is inevitable due to various mechanisms, such as the secondary mutation, T790M, activation of alternative pathways, C-MET, HGF, AXL. This article was authored by Li Wuhuang and Li Wufu.